By investing in the value chain of IVF with the right AI solutions, investors can solve the access problem growing in the IVF space, help more people build their families, and achieve significant ROI.
AI bridges the gap of human error and maximizes the potential success rates of IVF. AI’s ability to analyze big data paves the way for improving IVF outcomes and the development of evidence-based parameters that establish a consistent standard of care.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
By augmenting the embryologist in selecting the most viable embryo, there is potential for AI to help a patient conceive in one or two cycles, reducing the inherent cost of IVF therapy, and making the treatment more accessible to diverse populations that often don’t have ease of access to treatments today.
Through thoughtful consumer-centric design and application, these digital fertility solutions have the potential to smooth the path towards parenthood for countless couples and individuals around the world.
The lawsuit alleges that an Aetna policy discriminates against LGBTQ people by requiring them to pay thousands in out-of-pocket costs for fertility treatments before becoming eligible for coverage. Though Aetna has agreed to pay the costs incurred by the plaintiffs, the suit aims to strike down the policy as a whole.
Big name executives including former GE CEO Jeff Immelt, former Yahoo CEO Marissa Mayer, LinkedIn CEO Jeff Weiner and Levi’s CEO Chip Bergh also made personal investments in the company as part of the Series B round led by NEA.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company uses machine learning-based analysis of clinical data to help fertility clinics provide personalized patient reports with success probabilities for potential IVF participants.
Aspect Ventures led the $10 million Series A round. BBG Ventures, LaunchCapital, iNovia, RiverPark Ventures, Ulu Ventures, Day One Ventures and Portfolia participated.
Goodbye Obamacare, hello maple-leaf onesies?
Modern Family actress Sofia Vergara is being sued by her unborn embryos. It's a bizarre case that highlights the challenging intersection of science and family law, all while the Trump government gears up for a pro-life renaissance.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
TocopheRx is developing an infertility drug that's meant to sidestep IVF injections - converting in vitro fertilization into a completely oral regimen for both men and women. It's raising a $22 million Series A.
New York startup Celmatix just raised $5.5 million for its predictive software that determines a woman's likelihood of infertility based on her genomics.
In vitro fertilization is a tough process. Even if a set of embryos are able to form, it’s a real crapshoot to see which – if any – will actually be viable. Bay Area biotech Auxogyn has developed a test to track whether an embryo is developing successfully – and has raised a healthy swath of cash to commercialize its fresh-on-the-market […]